Method for preparing peritoneal dialysate

• US 7,297,689 B2
• Filed: 03/29/2005
• Issued: 11/20/2007
• Est. Priority Date: 08/24/1998
• Status: Expired due to Fees

• Current Assignee: Kiyoshi Kurokawa, Tokai University Educational System, Toshio Miyata
• Original Assignee: Kiyoshi Kurokawa, Tokai University Educational System, Toshio Miyata
• Inventors: Miyata, Toshio
• Primary Examiner(s): LEWIS, PATRICK T
• Application Number:
  US11/093,950
• Publication Number:
  US 20050267045A1
• Time in Patent Office: 966 Days
• Field of Search: 514/2, 514/23, 514/183
• US Class Current: 514/183
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/155 Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
• CPC Class Codes: A61K 31/203 Retinoic acids ; Salts thereof
• CPC Class Codes: A61K 31/4965 Non-condensed pyrazines
• CPC Class Codes: A61K 33/00 Medicinal preparations containing inorganic active ingredients
• CPC Class Codes: A61M 1/287 Dialysates therefor
• CPC Class Codes: A61P 13/12 of the kidneys
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 7/08 Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock artificial tears A61P27/04

Abstract

Carbonyl compounds generated and accumulated in the peritoneal dialysate can be inactivated or eliminated by a carbonyl compound-trapping agent such as aminoguanidine. Carbonyl compounds generated during sterilization and storage of the peritoneal dialysate can be eliminated by pre-contacting with the trapping agent. Further, it is possible to eliminate carbonyl compounds transferred from the blood to the peritoneal cavity of the patient during peritoneal dialysis treatment, by adding the trapping agent to the peritoneal dialysate or by circulating the fluid through a carbonyl compound-trapping cartridge. Intraperitoneal protein modification by carbonyl compounds is inhibited by the present invention, thereby sufficiently reducing peritoneal disorders associated with peritoneal dialysis treatment.

Claims

1. A method for preparing a peritoneal dialysate having a reduced carbonyl compound content, the method comprising:

(a) contacting the peritoneal dialysate with a surface having immobilized thereon a carbonyl compound-trapping agent; and

(b) separating the peritoneal dialysate from the surface having the carbonyl compound-trapping agent immobilized thereon;

wherein said carbonyl compound-trapping agent is selected from the group consisting of guanidine derivatives, hydrazine derivatives, 5-membered heterocyclic compounds having 2 nitrogen atoms, 5-membered heterocyclic compounds having 3 nitrogen atoms, 5-membered heterocyclic compounds having a nitrogen atom and a sulfur atom, 5-membered heterocyclic compounds having a nitrogen atom and an oxygen atom, nitrogen-containing 6-membered heterocyclic compounds, nitrogen-containing condensed heterocyclic compounds, sulfur and nitrogen-containing condensed heterocyclic compounds, sulfur-containing condensed heterocyclic compounds, oxygen-containing condensed heterocyclic compounds, nitrogenous compounds, quinones, aliphatic dicarboxylic acids, silicides, organogermanes, alkylamines, aromatic compounds, polypeptides, vitamins, SH group-containing compounds, SH group-containing proteins, biguanide agents, ion exchange resins, and inorganic compounds.

2. The method of claim 1, wherein the surface is on an insoluble carrier.

3. The method of claim 1, wherein the carbonyl compound-trapping agent is chosen from 2-isopropylidenehydrazono-4-oxo-thiazolidin-5-yl-acetanilide and aminoguanidine.

4. The method of claim 1, wherein the carbonyl compound-trapping agent comprises methylguanadine.

5. The method of claim 1, wherein the carbonyl compound-trapping agent comprises sulfonyihydrazine.

6. The method of claim 1, wherein the carbonyl compound-trapping agent is comprised of a compound chosen from pyrazolone, triazole, thiazoline, oxazole, pyridine, pyrimidine, benzothiazole, benzopyran, hydrazine, hydroquinone, benzoic acid, pyrrolonaphthyridinium, pyridoxamine, glutathione, cysteine, or N-acetylcysteine.

7. The method of claim 1, wherein the carbonyl compound-trapping agent comprises a composition chosen from activated charcoal, silica gel, alumina, and calcium carbonate.

8. The method of claim 1, wherein the carbonyl compound-trapping agent is chosen from activated charcoal, guanidine, aminoguanidine, biguanide, cysteine, and albumin.

9. A method, comprising the steps of:

passing a peritoneal dialysate through an adsorbent cartridge comprising an insoluble carbonyl compound-trapping agent;

allowing the peritoneal dialysate to remain in contact with the carbonyl-compound-trapping agent for a period of time and under conditions so as to allow carbonyl compounds present in the peritoneal dialysate to bind to the carbonyl-compound trapping agent; and

recovering peritoneal dialysate having a reduced carbonyl compound content as compared to peritoneal dialysate entering the adsorbent cartridge;

wherein said carbonyl compound-trapping agent is selected from the group consisting of guanidine derivatives, hydrazine derivatives, 5-membered heterocyclic compounds having 2 nitrogen atoms, 5-membered heterocyclic compounds having 3 nitrogen atoms, 5-membered heterocyclic compounds having a nitrogen atom and a sulfur atom, 5-membered heterocyclic compounds having a nitrogen atom and an oxygen atom, nitrogen-containing 6-membered heterocyclic compounds, nitrogen-containing condensed heterocyclic compounds, sulfur and nitrogen-containing condensed heterocyclic compounds, sulfur-containing condensed heterocyclic compounds, oxygen-containing condensed heterocyclic compounds, nitrogenous compounds, quinones, aliphatic dicarboxylic acids, silicides, organogermanes, alkylamines, aromatic compounds, polypeptides, vitamins, SH group-containing compounds, SH group-containing proteins, biguanide agents, ion exchange resins, and inorganic compounds.

10. The method of claim 9, wherein the carbonyl compound-trapping agent is immobilized on a surface.

11. The method of claim 9, wherein the surface is on an insoluble carrier.

12. The method of claim 9, wherein the carbonyl compound-trapping agent is chosen from aminoguanidine, 2-isopropylidenehydrazono-4-oxo-thiazolidin-5-yl-acetanilide and methylguanadine.

13. The method of claim 9, wherein the carbonyl compound-trapping agent comprises sulfonylhydrazine.

14. The method of claim 9, wherein the carbonyl compound-trapping agent is comprised of a compound chosen from pyrazolone, triazole, thiazoline, oxazole, pyridine, pyrimidine, benzothiazole, benzopyran, hydrazine, hydroquinone, benzoic acid, pyrrolonaphthyridinium, pyridoxamine, glutathione, cysteine, and N-acetylcysteine.

15. The method of claim 9, wherein the carbonyl compound-trapping agent comprises a composition chosen from activated charcoal, silica gel, alumina, and calcium carbonate.

16. The method of claim 9, wherein the carbonyl compound-trapping agent is chosen from activated charcoal, guanidine, aminoguanidine, biguanide, cysteine, and albumin.

17. A method, comprising the steps of:

(a) allowing peritoneal dialysate in a peritoneal cavity to contact a carbonyl compound-trapping agent; and

(b) allowing the carbonyl compound-trapping agent to trap a carbonyl compound;

wherein said carbonyl compound-trapping agent is selected from the group consisting of guanidine derivatives, hydrazine derivatives, 5-membered heterocyclic compounds having 2 nitrogen atoms, 5-membered heterocyclic compounds having 3 nitrogen atoms, 5-membered heterocyclic compounds having a nitrogen atom and a sulfur atom, 5-membered heterocyclic compounds having a nitrogen atom and an oxygen atom, nitrogen-containing 6-membered heterocyclic compounds, nitrogen-containing condensed heterocyclic compounds, sulfur and nitrogen-containing condensed heterocyclic compounds, sulfur-containing condensed heterocyclic compounds, oxygen-containing condensed heterocyclic compounds, nitrogenous compounds, quinones, aliphatic dicarboxylic acids, silicides, organogermanes, alkylamines, aromatic compounds, polypeptides, vitamins, SH group-containing compounds, SH group-containing proteins, biguanide agents, ion exchange resins, and inorganic compounds.

18. The method of claim 17, wherein the peritoneal cavity is in a dialysis patient.

19. The method of claim 17, wherein the carbonyl compound-trapping agent is directly infused into the peritoneal cavity.

20. The method of claim 17, wherein the carbonyl compound-trapping agent is chosen from aminoguanidine, 2-isopropylidenehydrazono-4-oxo-thiazolidin-5-yl-acetanilide and methylguanadine.

21. The method of claim 17, wherein the carbonyl compound-trapping agent comprises sulfonylhydrazine.

22. The method of claim 17, wherein the carbonyl compound-trapping agent is comprised of a compound chosen from pyrazolone, triazole, thiazoline, oxazole, pyridine, pyrimidine, benzothiazole, benzopyran, hydrazine, hydroquinone, benzoic acid, pyrrolonaphthyridinium, pyridoxamine, glutathione, cysteine, or N-acetylcysteine.

23. The method of claim 17, wherein the carbonyl compound-trapping agent comprises a composition chosen from activated charcoal, silica gel, alumina, and calcium carbonate.

24. The method of claim 17, wherein the carbonyl compound-trapping agent is chosen from activated charcoal, guanidine, aminoguanidine, biguanide, cysteine, and albumin.

25. The method of claim 17, wherein the carbonyl compound-trapping agent is administered by intravenous injection.

26. A method for trapping a carbonyl compound in a peritoneal dialysate for peritoneal dialysis treatment, comprising the steps of:

(a) adding a carbonyl compound-trapping agent to peritoneal dialysate prior to dialysis treatment; and

(b) allowing the carbonyl compound-trapping agent to trap a carbonyl compound;

wherein said carbonyl compound-trapping agent is selected from the group consisting of guanidine derivatives, hydrazine derivatives, 5-membered heterocyclic compounds having 2 nitrogen atoms, 5-membered heterocyclic compounds having 3 nitrogen atoms, 5-membered heterocyclic compounds having a nitrogen atom and a sulfur atom, 5-membered heterocyclic compounds having a nitrogen atom and an oxygen atom, nitrogen-containing 6-membered heterocyclic compounds, nitrogen-containing condensed heterocyclic compounds, sulfur and nitrogen-containing condensed heterocyclic compounds, sulfur-containing condensed heterocyclic compounds, oxygen-containing condensed heterocyclic compounds, nitrogenous compounds, quinones, aliphatic dicarboxylic acids, silicides, organogermanes, alkylamines, aromatic compounds, polypeptides, vitamins, SH group-containing compounds, SH group-containing proteins, biguanide agents, ion exchange resins, and inorganic compounds.

27. The method of claim 26, wherein the carbonyl compound-trapping agent is chosen from 2-isopropylidenehydrazono-4-oxo-thiazolidin-5-yl-acetanilide and aminoguanidine.

28. The method of claim 26, wherein the carbonyl compound-trapping agent comprises methylguanadine.

29. The method of claim 26, wherein the carbonyl compound-trapping agent comprises sulfonyihydrazine.

30. The method of claim 26, wherein the carbonyl compound-trapping agent is comprised of a compound chosen from pyrazolone, triazole, thiazoline, oxazole, pyridine, pyrimidine, benzothiazole, benzopyran, hydrazine, hydroquinone, benzoic acid, pyrrolonaphthyridinium, pyridoxamine, glutathione, cysteine, or N-acetylcysteine.

31. The method of claim 26, wherein the carbonyl compound-trapping agent comprises a composition chosen from activated charcoal, silica gel, alumina, and calcium carbonate.

32. The method of claim 26, wherein the carbonyl compound-trapping agent is chosen from activated charcoal, guanidine, aminoguanidine, biguanide, cysteine, and albumin.